LivaNova PLC (LIVN)

NASDAQ · Instruments & Medical Devices · Electromedical & Electrotherapeutic Apparatus

Price
$77.16
Day
-1.69%
Market cap
$4.25B
P/E
22.6

Close 2026-09-23.

The company

Business Overview LivaNova identifies operating segments based on how it manages, evaluates, and internally reports its business activities to allocate resources, develop and execute its strategy, and assess performance. LivaNova has two reportable segments: Cardiopulmonary and Neuromodulation. “Other” includes non-allocated corporate expenses and the non-cannula results of the Company’s former ACS segment, which was wound down during 2024. For additional information regarding LivaNova’s reportable segments, historical financial information, and methodology for the presentation of financial results, refer to “Part IV, Item 15. Exhibits and Financial Statement Schedules” of this Report.

From Item 1: Business Overview.

By business segment

Institutional holders

Largest positions reported on Form 13F for the quarter ended 2026-06-30, by value.

Insider trades

Open-market buys and sales filed on Form 4, newest first. Grants, option exercises and tax withholding are left out.

Recent filings